{{Drugbox
| IUPAC_name = (17-acetyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl) hexanoate
| image = Gestronol caproate.svg
| width = 250

<!--Clinical data-->
| tradename = Depostat, Primostat
| pregnancy_category =  
| legal_status = Rx-only
| routes_of_administration = [[Intramuscular injection]]<ref name="Muller1998" /><ref name="Aronson2009">{{cite book|author=Jeffrey K. Aronson|title=Meyler's Side Effects of Endocrine and Metabolic Drugs|url=https://books.google.com/books?id=BWMeSwVwfTkC&pg=PA289|date=21 February 2009|publisher=Elsevier|isbn=978-0-08-093292-7|pages=289–}}</ref><ref name="MortonHall2012" />

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| excretion =

<!--Identifiers-->
| ATC_prefix = G03
| ATC_suffix = DA01
| ATC_supplemental = <br />{{ATC|L02|AB03}}
| CAS_number = 1253-28-7
| PubChem = 443881
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 391969

<!--Chemical data-->
| C = 26 | H = 38 | O = 4
| molecular_weight = 414.57752 g/mol
| smiles = CCCCCC(=O)OC1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34)C)C(=O)C
| StdInChI = 1S/C26H38O4/c1-4-5-6-7-24(29)30-26(17(2)27)15-13-23-22-10-8-18-16-19(28)9-11-20(18)21(22)12-14-25(23,26)3/h16,20-23H,4-15H2,1-3H3/t20-,21+,22+,23-,25-,26-/m0/s1
| StdInChIKey = XURCMZMFZXXQDJ-UKNJCJGYSA-N
| synonyms = <small>SH-582, SH-80582, NSC-84054; Gestonorone hexanoate, Gestronol hexanoate, Gestronol caproate, Norhydroxyprogesterone caproate; 17α-Hydroxy-19-norpregn-4-ene-3,20-dione hexanoate; 17α-hydroxy-19-norprogesterone hexanoate</small>
}}

'''Gestonorone caproate''', or '''gestronol hexanoate''', also under the brand names '''Depostat''' and '''Primostat''', is a [[progestin]] which is used in the treatment of [[benign prostatic hypertrophy]] and [[endometrial cancer]].<ref name="Muller1998">{{cite book|author=Muller|title=European Drug Index: European Drug Registrations, Fourth Edition|url=https://books.google.com/books?id=HiSdvzs2pPAC&pg=PA338|date=19 June 1998|publisher=CRC Press|isbn=978-3-7692-2114-5|pages=338–}}</ref><ref name="MortonHall2012">{{cite book|author1=I.K. Morton|author2=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA132|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1|pages=132–}}</ref><ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA595|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=595–}}</ref><ref name="IndexNominum2000">{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA1361|date=January 2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|page=488}}</ref><ref name="Publishing2013">{{cite book|author=William Andrew Publishing|title=Pharmaceutical Manufacturing Encyclopedia, 3rd Edition|url=https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA1761|date=22 October 2013|publisher=Elsevier|isbn=978-0-8155-1856-3|pages=1761–1762}}</ref><ref name="Thurston2006">{{cite book|author=David E. Thurston|title=Chemistry and Pharmacology of Anticancer Drugs|url=https://books.google.com/books?id=5uB19xhhyDsC&pg=PA154|date=22 November 2006|publisher=CRC Press|isbn=978-1-4200-0890-6|pages=154–155}}</ref> It is not active [[oral administration|by mouth]] and must be administered by [[intramuscular injection|injection into muscle]].

==Pharmacology==
Gestonorone caproate is a strong, long-acting, and pure [[progestogen]],<ref name="Raspé2013">{{cite book|author=G. Raspé|title=Hormones and Embryonic Development: Advances in The Biosciences|url=https://books.google.com/books?id=Xp3pAgAAQBAJ&pg=PA79|date=22 October 2013|publisher=Elsevier Science|isbn=978-1-4831-5171-7|pages=79}}</ref><ref name="SchooneesDe Klerk1969">{{cite journal|last1=Schoonees|first1=R.|last2=De Klerk|first2=J. N.|last3=Murphy|first3=G. P.|title=The effect of depostat (SH 582) on the baboon prostate|journal=Journal of Surgical Oncology|volume=1|issue=4|year=1969|pages=317–324|issn=0022-4790|doi=10.1002/jso.2930010404}}</ref> possessing no [[androgen]]ic, [[anabolic]], [[antiandrogen]]ic, [[estrogen]]ic, [[antiestrogen]]ic, [[corticosteroid]], or [[teratogen]]ic effects.<ref name="Schering1968">Schering A.G., Berlin (1968). Depostat (SH 582) a new treatment for prostatic hypertrophy.</ref><ref name="AubreyKhosla1971">{{cite journal|last1=Aubrey|first1=D. A.|last2=Khosla|first2=T.|title=The effect of 17-alpha-hydroxy-19-norprogesterone caproate (SH 582) on benign prostatic hypertrophy|journal=British Journal of Surgery|volume=58|issue=9|year=1971|pages=648–652|issn=0007-1323|doi=10.1002/bjs.1800580904}}</ref> In animals, it is approximately 25&nbsp;times more potent than [[progesterone]] or [[hydroxyprogesterone caproate]].<ref name="AubreyKhosla1971" /> In humans, 100 or 200&nbsp;mg intramuscular gestonorone caproate is said to be equivalent to 1000&nbsp;mg intramuscular hydroxyprogesterone caproate.<ref name="pmid5556820">{{cite journal | vauthors = Karlstedt K | title = Progesterone treatment for local recurrence and metastases in carcinoma corporis uteri | journal = Acta Radiologica: Therapy, Physics, Biology | volume = 10 | issue = 2 | pages = 187–92 | year = 1971 | pmid = 5556820 | doi = 10.3109/02841867109129755| url = | quote = The preparations used were Proluton Depot (17a-hydroxy-progesterone caproate) and in 3 patients SH 5132 (17a-hydroxy-19-norprogesterone caproate); 100 mg of the latter corresponds to 1000 mg of Proluton Depot.}}</ref><ref name="pmid4261828">{{cite journal | vauthors = Moe N | title = Short-term progestogen treatment of endometrial carcinoma. Histological, histochemical and hormonal studies | journal = Acta Obstet Gynecol Scand | volume = 51 | issue = 1 | pages = 55–62 | year = 1972 | pmid = 4261828 | doi = 10.3109/00016347209154968| url = | quote = Thirteen patients with primary adenocarcinoma of the uterine corpus were treated for 21 days with l7alphahydroxy-progesterone-caproate (Primolut Depot@, Schering), 1000 mg daily, or 17alpha-hydroxy-19-nor-progesterone-caproate (DepostatB, Schering), 200 mg daily. These doses can be considered as equivalent.}}</ref>

Like other potent progestins, gestonorone caproate possesses potent [[antigonadotropic]] activity and is capable of markedly suppressing the [[gonad]]al production and circulating levels of sex hormones such as [[testosterone]] and [[estradiol]].<ref name="AubreyKhosla1971" /><ref name="RaspéBrosig2013">{{cite book|author1=G. Raspé|author2=W. Brosig|title=International Symposium on the Treatment of Carcinoma of the Prostate, Berlin, November 13 to 15, 1969: Life Science Monographs|url=https://books.google.com/books?id=8RjLBAAAQBAJ&pg=PA169|date=22 October 2013|publisher=Elsevier|isbn=978-1-4831-8711-2|pages=169}}</ref><ref name="MakrigiannisGaca1971">{{cite journal|last1=Makrigiannis|first1=D.|last2=Gaca|first2=A.|title=Evaluation of Depostat R in prostatic adenoma on the ground of clinical and sphincterotonometric studies|journal=International Urology and Nephrology|volume=3|issue=1|year=1971|pages=21–29|issn=0301-1623|doi=10.1007/BF02081794}}</ref> A clinical study found that 400&nbsp;mg/week intramuscular gestonorone caproate suppressed testosterone levels by 75% in men, while [[orchiectomy]] as a comparator reduced testosterone levels by 91%.<ref name="pmid694436">{{cite journal | vauthors = Sander S, Nissen-Meyer R, Aakvaag A | title = On gestagen treatment of advanced prostatic carcinoma | journal = Scand. J. Urol. Nephrol. | volume = 12 | issue = 2 | pages = 119–21 | year = 1978 | pmid = 694436 | doi = | url = }}</ref><ref name="pmid519881">{{cite journal | vauthors = Kjeld JM, Puah CM, Kaufman B, Loizou S, Vlotides J, Gwee HM, Kahn F, Sood R, Joplin GF | title = Effects of norgestrel and ethinyloestradiol ingestion on serum levels of sex hormones and gonadotrophins in men | journal = Clinical Endocrinology | volume = 11 | issue = 5 | pages = 497–504 | year = 1979 | pmid = 519881 | doi = 10.1111/j.1365-2265.1979.tb03102.x| url = | quote = Another synthetic gestogen, 17-hydroxy-19-norprogesterone caproate (Depostat-Schering), 400 mg by i.m. weekly injections suppressed T levels to 25% of pretreatment values (Sander er al., 1978).}}</ref> Levels of [[luteinizing hormone]], conversely, remained unchanged.<ref name="pmid694436" /> Gestonorone caproate is administered once weekly by intramuscular injection, via which it acts as a [[depot injection|depot]].<ref name="Denis2012">{{cite book|author=Louis Denis|title=The Medical Management of Prostate Cancer|url=https://books.google.com/books?id=T78hBQAAQBAJ&pg=PT112|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-73238-6|pages=112â€“|quote=Gestonorone caproate, another progestational agent, was investigated at our institution. Eighteen patients with painful metastatic [prostate cancer] with objective relapse after orchiectomy were treated with 400 mg/week i.m.}}</ref><ref name="RunnebaumRabe2012">{{cite book|author1=Benno Clemens Runnebaum|author2=T. Rabe|author3=L. Kiesel|title=Future Aspects in Contraception: Proceeding of an International Symposium held in Heidelberg, 5â€“8 September 1984 Part 1 Male Contraception|url=https://books.google.com/books?id=GX2oBgAAQBAJ&pg=PA133|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-009-4910-2|pages=133â€“|quote=Gestonorone [caproate] 100 or 200 mg/week i.m.}}</ref><ref name="PalancaJuco2008">{{cite journal|last1=Palanca|first1=Ernesto|last2=Juco|first2=Wilfrido|title=Conservative treatment of benign prostatic hyperplasia|journal=Current Medical Research and Opinion|volume=4|issue=7|year=2008|pages=513â€“520|issn=0300-7995|doi=10.1185/03007997709109342|quote=A study was carried out in 30 male patients with benign prostate hyperplasia to assess the effectiveness of treatment with a progestational agent, gestonorone caproate (200 mg), given intramuscularly every 7 days over a period of 2 to 3 months.}}</ref>

Like the closely related progestins hydroxyprogesterone caproate and 19-norprogesterone, gestonorone caproate shows poor activity [[oral administration|oral]]ly and must be administered [[parenteral]]ly; specifically, via [[intramuscular injection]].<ref name="pmid4285463">{{cite journal | vauthors = Breuer H, Lisboa BP | title = [Studies on the metabolism of 17-alpha-hydroxy-19-norprogesterone caproate by humans in vivo and of 17-alpha-hydroxy-19-norprogesterone by rats in vitro] | language = German | journal = Acta Endocrinologica | volume = 51 | issue = 1 | pages = 114–30 | year = 1966 | pmid = 4285463 | doi = | url = }}</ref>

==Chemistry==
{{See also|List of steroidal progestogens|Progestogen ester}}

Gestonorone caproate, also known as '''norhydroxyprogesterone caproate''', '''17α-hydroxy-19-norprogesterone 17α-hexanoate''', or '''17α-hydroxy-19-norpregn-4-ene-3,20-dione 17α-hexanoate''', is a [[synthetic compound|synthetic]] [[norpregnane]] [[steroid]] and a [[chemical derivative|derivative]] of [[progesterone]].<ref name="Elks2014" /><ref name="IndexNominum2000" /> It is specifically a combined derivative of [[17α-hydroxyprogesterone]] and [[19-norprogesterone]], or of [[gestronol]] (17α-hydroxy-19-norprogesterone), with a [[hexanoate]] (caproate) [[ester]] at the C17α position.<ref name="Elks2014" /><ref name="IndexNominum2000" /> [[Structural analogue|Analogue]]s of gestonorone caproate include [[algestone acetophenide]] (dihydroxyprogesterone acetophenide), [[demegestone]], [[hydroxyprogesterone caproate]], [[nomegestrol acetate]], [[norgestomet]], and [[segesterone acetate]] (nestorone).<ref name="Elks2014" /><ref name="IndexNominum2000" />

==History==
Gestonorone caproate was developed by [[Schering AG|Schering]] and has been marketed since at least 1973.<ref name="SubbiahMortensen1973">{{cite journal|last1=Subbiah|first1=N.|last2=Mortensen|first2=James|title=The Treatment of Benign Enlargement of the Prostate with Nor Progesterone Caproate (Primostat)|journal=ANZ Journal of Surgery|volume=42|issue=3|year=1973|pages=304–307|issn=1445-1433|doi=10.1111/j.1445-2197.1973.tb06805.x}}</ref>

==Society and culture==

===Generic names===
''Gestonorone caproate'' is the [[generic term|generic name]] of the drug and its {{abbrlink|INN|International Nonproprietary Name}}, {{abbrlink|USAN|United States Adopted Name}}, and {{abbrlink|JAN|Japanese Accepted Name}}, while ''gestronol hexanoate'' is its {{abbrlink|BANM|British Approved Name}}.<ref name="Elks2014" /><ref name="IndexNominum2000" />

===Availability===
Gestonorone caproate is available widely in [[Europe]], including in the [[United Kingdom]], and is also marketed in [[Japan]], [[China]], [[Mexico]], and certain other countries.<ref name="Muller1998" /><ref name="IndexNominum2000" /><ref name="Drugs.com">https://www.drugs.com/international/gestonorone-caproate.html</ref> It is not available in the [[United States]], [[Canada]], and many other countries throughout the world.<ref name="IndexNominum2000" /><ref name="Drugs.com" />

==Research==

===Breast cancer===
'''SH-834''' was a combination of 90&nbsp;mg [[estradiol valerate]] and 300&nbsp;mg gestonorone caproate for weekly intramuscular injection that was developed by Schering in the 1970s.<ref name="NotterBerndt2009">{{cite journal|last1=Notter|first1=G.|last2=Berndt|first2=G.|title=Hormonal Treatment of Mammary Carcinoma with Progynon-Depot and Depostat|journal=Acta Radiologica: Therapy, Physics, Biology|volume=14|issue=5|year=2009|pages=433–442|issn=0567-8064|doi=10.3109/02841867509132684}}</ref><ref name="Ward1972">{{cite journal|last1=Ward|first1=H. W. C.|title=PROGESTOGEN THERAPY FOR OVARIAN CARCINOMA|journal=BJOG: An International Journal of Obstetrics and Gynaecology|volume=79|issue=6|year=1972|pages=555–559|issn=1470-0328|doi=10.1111/j.1471-0528.1972.tb14200.x}}</ref> It was investigated clinically as a treatment for [[breast cancer]] and was found to be effective, but does not seem to have been marketed.<ref name="NotterBerndt2009" /><ref name="BerndtStender2009">{{cite journal|last1=Berndt|first1=G.|last2=Stender|first2=H.-St.|title=[The combined estrogen-gestagen treatment of metastasizing mammary carcinoma using with SH 834]|volume=95|issue=48|year=2009|pages=2399–2404|issn=0012-0472|doi=10.1055/s-0028-1108843}}</ref><ref>http://www.popline.org/node/485956</ref>

==References==
{{Reflist|2}}


{{Drugs used in benign prostatic hypertrophy}}
{{Progestogens and antiprogestogens}}
{{Progesterone receptor modulators}}

[[Category:Antigonadotropins]]
[[Category:Drugs for benign prostatic hyperplasia]]
[[Category:Enantiopure drugs]]
[[Category:Hormonal antineoplastic drugs]]
[[Category:Norpregnanes]]
[[Category:Progestogen esters]]
[[Category:Progestogens]]